Utilizing CGM Ambulatory Glucose Profiles to Optimize Diabetes Management

LEARNING OBJECTIVES
At the end of the activity, participant will be able to:
• Identify patients who could benefit from continuous glucose monitoring (CGM) vs fingerstick blood glucose monitoring.
• List the types of information provided by CGM systems.
• Interpret CGM data using the ambulatory glucose profile (AGP) to assess if the patient is achieving targets established by the
International Consensus on Time in Range.
• Modify the treatment plan based on CGM data to improve patient outcomes.
KEY TAKEAWAYS
• Continuous glucose monitoring (CGM) overcomes some of the limitations of glycated hemoglobin and fingerstick selfmonitoring of blood glucose.
• The standardized AGP and time in range have been established to serve as an actionable format for presenting and interpreting CGM data.
• For most healthy adults with type 1 or type 2 diabetes, the desired target for time in range is ≥70%.
• The AGP provides glycemic patterns that facilitate the identification of glucose variability, hyperglycemic episodes, and individuals at high hypoglycemic risk.
• The AGP is particularly useful for individuals treated with insulin, but benefits of CGM and AGP are not limited to individuals using insulin.
• The AGP provides an excellent opportunity for shared decision-making.
Primary Care Education Consortium designates this enduring material for a maximum of 1.0 AMA PRA Category 1 credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME is available from August 1, 2021 to July 31, 2022. To receive CME credit, visit https://www.pcmg-us.org/survey/agpht.
PAs AND NURSE PRACTITIONERS: AANP, ANCC, and AAPA accept certificates of participation from educational activities
certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Visit https://www.pcmg-us.org/survey/agpht
to receive the certificate